Related Experiment Videos
Modulation of vascular inflammation by PPARs
Doris M Tham1, Yi-Xin Wang, John C Rutledge
1Department of Internal Medicine, School of Medicine, University of California at Davis, USA. doris.tham@stanfordalumni.org
Drug News & Perspectives
|June 7, 2003
Summary
Peroxisome proliferator-activated receptors (PPARs) reduce inflammation in atherosclerosis. PPAR agonists offer a potential therapy by targeting arterial wall inflammation and preventing disease progression.
Area of Science:
- Cardiovascular Biology
- Immunology
- Molecular Medicine
Background:
- Atherosclerotic lesions involve chronic inflammation driven by cell activation and proinflammatory molecule release.
- Peroxisome proliferator-activated receptors (PPARs) exhibit anti-inflammatory effects in key vascular and immune cells.
- PPARs regulate genes critical to vascular inflammation and atherogenesis.
Purpose of the Study:
- To review the current understanding of PPARs and their anti-inflammatory roles.
- To explore the mechanisms by which PPAR agonists combat atherogenesis.
- To highlight PPAR agonists as potential therapeutic agents for atherosclerosis.
Main Methods:
- Review of existing scientific literature on PPARs and atherosclerosis.
- Analysis of gene expression regulation by PPARs in relevant cell types.
- Examination of proposed mechanisms of action for PPAR agonists.
Main Results:
- PPARs modulate the transcription of proinflammatory genes (cytokines, chemokines, adhesion molecules, metalloproteinases).
- PPARs influence monocyte/macrophage recruitment and foam cell formation in the arterial wall.
- PPAR agonists demonstrate direct anti-inflammatory and antiatherogenic actions.
Conclusions:
- PPAR agonists represent a promising therapeutic strategy for atherosclerosis.
- Targeting PPARs can modulate the inception and progression of arterial wall inflammation.
- Further research into PPAR mechanisms may yield novel antiatherogenic treatments.